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An Abstract of the Scholarly Project by
Morgan B. Baxter

This scholarly project included an education presentation to Pittsburg State
University students enrolled in the Health Promotion class in the Fall of 2019, a pretest
was taken before the educational presentation and then a posttest was completed to assess
the student’s knowledge of HPV and the HPV vaccine. The posttest evaluated whether
there was an increase in knowledge after the presentation. In this scholarly project there
was an overall increase in knowledge with statistical significance (p<0.05) after the
presentation of evidence-based practice information of HPV and the HPV vaccine. There
was an increase in posttest scores after the presentation in all participants (n=58). Current
research states overall low HPV vaccine uptake and this study shows that many college
students are not aware of HPV and HPV vaccine evidence-based information. This
project validates the need for continued education for students of HPV and the HPV
vaccine.
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CHAPTER I

Introduction

The most common sexually transmitted infection (STI) is the human
papillomavirus (HPV). HPV is a family of viruses that infects the epithelial tissue of
males and females. Many people are exposed to this virus without symptoms. Before
there was a vaccine for HPV, approximately 17 million young adults aged 15-24 years
old had a prevalent HPV infection. It is likely almost every person will be infected with
HPV in their lifetime (Centers for Disease Control and Prevention, 2019). Due to the
many different strands of HPV sometimes the body is able to get rid of the disease
without symptoms or disease and other times the strand can cause the person cancer. The
STI is known to cause at least six types of cancer and genital warts (Satterwhite et al.,
2013). More than 90% of cervical cancer and 63-75% of vulvar, vaginal, oropharyngeal,
and penile cancer can be linked to HPV (Steinau et al., 2013). A vaccine was approved in
2014 that prevents HPV and HPV outcome related diseases (Centers for Disease Control
and Prevention [CDC], n.d.). The HPV vaccine uptake has increased since 2013, from
19.6% to 29.5% of Kansans being vaccinated. This is significantly below the Healthy
People 2020 goal of 80% vaccine uptake (Gillespie, 2018). The HPV vaccine is essential
to the public to protect from diseases that have serious side effects and can possibly result
in death.
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Background
There are more than 150 subtypes of HPV that have been identified. Some HPV
subtypes can cause common warts, such as those on the hands and feet by infecting
cutaneous epithelial cells. At least 40 of the subtypes of HPV can involve the areas of
genitals, mouth, and throat by infecting the mucosal epithelial cells. (CDC, n.d.). Once
infected with HPV many people do not know they have the virus bec ause they
are asymptomatic and resolve without complication. In some cases, HPV lasts
longer than two years and can cause certain cancers of the cervix, vulva, and
vagina, in women; cancer of the penis in men; and cancers of the back of the
throat, anus, tongue, and tonsils in both genders (CDC, 2018c). HPV type 16 and
18 are high-risk viruses and cause 80% of the cancers from HPV. Genital warts
and possibly laryngeal papillomas are caused by the lower risk HPV types. Both
subtypes can cause low-grade cervical cell changes. Low-risk HPV types 6 and
11 almost always cause genital warts and papillomas (CDC, n.d.)
HPV is spread by anal, vaginal, and oral sex, with someone who has the
HPV virus. The virus is most commonly spread by vaginal and anal sex. In the
United States, there have been three different HPV vaccines available: two are
U.S. Food and Drug Administration (FDA) approved include Gardasil
(Quadrivalent) and Gardasil 9 (9-valent). Gardasil 9 was approved in 2014, it
was studied with more than 15,000 participants before the vaccine was released
and is continually monitored by the CDC. Gardasil 9 has been the only HPV
vaccine available since 2016 in the United States. This vaccine protects against
HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58, which includes seven types that
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cause cancer. The original Gardasil was approved in 2006, this vaccine was
tested was on more than 29,000 individuals. Gardasil protects against HPV types
6, 11, 16, and 18 (CDC, 2018d). Cervarix, the 3 rd HPV vaccine has been
discontinued due to lack of use because of Gardasil. HPV causes approximately
32,500 cancers each year, 30,000 of those are preventable with the current HPV
vaccine (CDC, n.d.)
The HPV vaccine is recommended for patients between the ages of 9 to 26 for
women ages 9 though 21 for men. The vaccine is recommended for transgender patients
and for men that have sex with men until age 26. Recommendations state children age 11
or 12 should get the vaccine before they become sexually active and can receive the
vaccine as early as nine years old. Two vaccines six to 12 months apart are required to be
fully vaccinated against HPV. If the child is over 14 years of age the child still qualifies
for the vaccine, but three injections are needed six months apart to be fully vaccinated
against HPV. If a patient is immunocompromised, three doses is recommended regardless
of age or gender (CDC, 2018c). Recommendations are to receive the full recommended
doses of the HPV vaccine before becoming exposed to HPV. Even if you contract one
strain of HPV the vaccine will protect you from the other strains of HPV the vaccine
covers. The vaccine can still be given if the person receiving the vaccine is ill with a
minor illness such as an upper respiratory tract infection, without or with a fever, or
diarrhea. If a woman has had an abnormal pap, positive HPV test, or genital warts she is
still able to receive the vaccine, but the vaccine may not be as effective based on the
existing HPV infection. Women that are currently breastfeeding are able to safely obtain
the HPV vaccine. Contraindications of vaccine administration includs anyone with a
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known allergy to the Gardasil vaccine or hypersensitivity to yeast, a severe or moderate
illness, and pregnancy. Although studies have shown the HPV vaccine does not harm the
mother or fetus. A negative pregnancy test is not needed before vaccine administration
(Centers for Disease Control and Prevention, n.d.) The vaccination is not recommended
for adults older than 26 years of age since the vaccination provides less benefit from
possible prior exposure to HPV. Engaging with a new sexual partner is a risk for a new
HPV infection. The vaccine will not treat any existing HPV infections but does prevent
new HPV infections (CDC, 2019).
Research conducted in Kansas states that females are twice as likely to receive at
least one dose of the vaccine compared to males. If the child is older, 15 to 17 years of
age, they are twice as likely to receive at least one dose of the vaccine compared to
younger children. Also, in Kansas it was shown that more populated urban counties are
1.5 times likely to receive at least one dose of the vaccine compared to rural counties
(Gillespie, 2018). One reason children are not being vaccinated is low caregiver
education level (Forshaw et al., 2017). There are many different reasons parents choose
not to vaccinate or delay vaccination including: medical, religious, philosophical, or
socioeconomic status (Ventola, 2016).
Significance of the Problem
HPV is a virus that is very common. Approximately 80 million or one in four
people have the HPV virus in the United States. On average, 14 million people contract
the HPV virus every year, mostly teens and young adults. Yearly HPV causes 33,700
cancers in women and men from the HPV infection (Centers for Disease Control and
Prevention, 2018c). Although HPV is known for causing cervical cancer, HPV causes
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20,000 approximately cancers that are non-cervical each year in the United States.
Oropharyngeal cancer caused by the HPV infection affects approximately 10,100 men in
the United States each year. Approximately 12,000 women are diagnosed with cervical
cancer each year with recommended screening and treatment. It is said that more than
4,000 women die every year in this country from cervical cancer (Centers for Disease
Control and Prevention, n.d.).
The only cancer caused by HPV providers screen for routinely is cervical cancer.
Other types of HPV are not usually detected and explored until the person becomes
symptomatic. Because of this prevention is key. Starting at age 21 routine cervical cancer
screening begins and continues through age 65. Even with the HPV vaccine, routine
cervical cancer screenings should take place as recommended. The HPV vaccine is safe
and effective. Several studies have shown the vaccine to be effective in protecting against
HPV for greater than 10 years. Ongoing research is being conducted on HPV and the
HPV vaccine (Centers for Disease Control and Prevention, n.d.). Despite this research
vaccination rates remain lower than the Healthy People 2020 goal of 80% vaccination
uptake in Kansas and United States as a whole (Gillespie, 2018).
Significance to Nursing
This subject plays a part to nursing in many ways. Advanced practice
registered nurses (APRN) manage many individuals preventative care. Educating
the patient as well as their parent or guardian if applicable of HPV and the
benefits of the HPV vaccine is essential. Health care providers are key in routine
gynecological exams that screen for HPV and provide treatment for HPV if
needed.
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Specific Aims/Purpose
This study will assess the knowledge of a health promotion class in the fall of
2019 at Pittsburg State University in Pittsburg, Kansas, before and after an educational
presentation of HPV and the HPV vaccine, by survey administration. Resources of where
the HPV vaccine can be obtained will be communicated to the students.
The aims of this study includes informing college students about HPV and the
HPV vaccine and assessing knowledge before and after education is obtained about HPV
and the HPV vaccine. The students in this project are enrolled in the fall 2019 Health
Promotion class offered at Pittsburg State University. This class is open to all majors
including pre-nursing and exercise science. It is possible that many of these students will
one day be in involved in healthcare. This will likely increase knowledge of HPV and
HPV vaccine in the healthcare field and the general public.
Theoretical Framework
The Health Belief Model (HBM) can be applied to increasing HPV and HPV
vaccine knowledge and uptake. This model was initially used on low response of free
tuberculosis screening. Since the 1950’s, this framework is often used to understand
health behavior and promote health practices (University of Twente, 2017).
There are three major assumptions of this framework. The HBM implies that a
person will engage in a health-related action if the person feels the undesirable health
condition can be avoided; has an expectation that by utilizing a recommended practice,
he/she avoid the undesirable health condition; and believes that he/she can successfully
take the suggested health action. There are six concepts to this model including:
perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cues
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to action, and self-efficacy. All assumptions and concepts of this model can be applied to
this topic (University of Twente, 2017).
Table 1:
Application of the Health Belief Model
Concept
1. Perceived susceptibility

2.

Perceived severity

3.

Perceived benefits

4.

Perceived barriers

5.

Cues to action

6.

Self-efficacy

Definition
“One's opinion of
chances of getting a
condition”
“One's opinion of how
serious a condition and
its consequences are”

HPV vaccine
Persons <26 years of age
believe they can acquire
HPV.
Persons <26 believe that the
consequences of getting
HPV are significant enough
to try to avoid.
“One's belief in the
Persons <26 believe that the
efficacy of the advised suggested action of the HPV
action to reduce risk or vaccine would protect them
seriousness of impact”
from getting HPV.
“One's opinion of the
Persons <26 identify
tangible and
personal barriers to getting
psychological costs of
the HPV vaccine and
the advised action”
explore ways to eliminate or
reduce barriers.
“Strategies to activate
HPV vaccine information
"readiness””
will be presented. An
incentive will be presented
to Persons <26 who receive
the HPV vaccine.
“Confidence in one's
Persons <26 will be
ability to take action”
confident in the HPV
vaccine protecting them
against HPV.
Reproduced from University of Twente, 2017
Project Questions

The practice problem identified is low HPV vaccine rates in the state of Kansas,
this leads to increased risk and exposure of HPV that can lead to cancer and other chronic
health conditions. The aim of this project is to evaluate the knowledge of HPV and the
HPV vaccine and educate a group of Pittsburg State University health promotion students
7

with evidence-based facts. This project will assess whether the education provided
increased knowledge of HPV and the HPV vaccine. Research questions in this project
include:
1. What are the demographics (gender and age) of the respondents?
2. Will students have heard of the HPV vaccine pre-education?
3. Will students have heard of HPV pre-education?
4. What is the respondent’s HPV knowledge pre-education?
5. Has a healthcare provider recommended the HPV vaccine to the respondent?
6. Has the respondent received at least one dose of the HPV vaccine series?
7. What is the respondent’s HPV knowledge post-education?
8. Did education increase the knowledge of HPV post-education?
Definition of Key Terms/Variables
Terms that may not be recognized by colleagues or review include: Centers for
Disease Control and Prevention (CDC), college-aged, Gardasil, Gardasil 9, human
papillomavirus (HPV), immunity, vaccination, vaccine, and vaccination uptake.
1. Centers for Disease Control and Prevention (CDC) – A major group that
oversees and tracks health related issues and diseases for the United States
government. The CDC is an agency that is recognized as the nation’s
premiere health promotion, preparedness, and prevention agency (Centers
for Disease Control and Prevention, 2018a).
2. College-aged – The general age in which students generally attend a
higher education, typically 18-24 (YourDictionary, 2019).
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3. Gardasil – The first approved HPV vaccine in 2006. Safety of this vaccine
was proven by clinical trials of more than 29,000 participants and
continues to be monitored. This vaccine only protects against 4 strains of
HPV: 6, 11, 18, and 18 (CDC, 2018d).
4. Gardasil 9 (9-valent) – Also referred to as the HPV vaccine. The only
current HPV vaccine used in the United States that prevents nine types of
HPV: 6, 11, 16, 18, 31, 33, 45, 52, and 58. This vaccine was studied with
15,000 participants before approved by the FDA in 2014 and continues to
be monitored (CDC, 2018d).
5. Human papillomavirus (HPV) – “A type of virus that can cause abnormal
tissue growth (for example, warts) and other changes to cells. Infection for
a long time with certain types of human papillomavirus can cause cervical
cancer. Human papillomavirus may also play a role in some other types of
cancer, such as anal, vaginal, vulvar, penile, and oropharyngeal cancers.
Also called HPV” (National Cancer Institute, n.d, para 1).
6. Immunity – protection from a disease, if exposed you will not be infected
(CDC, 2018e).
7. Immunization – the process of obtaining protection though vaccination
from diseases, also used interchangeably with vaccination, inoculation, or
vaccination uptake (CDC, 2018e)
8. Vaccination – receiving a vaccine that will allow the body to gain
immunity against a specific disease; inoculation (Lexico, 2019)
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9. Vaccine – “A product that stimulates a person’s immune system to
produce immunity to a specific disease, protecting the person from that
disease. Vaccines are usually administered through needle injections but
can also be administered by mouth or sprayed into the nose” (CDC, 2018e,
para 2).
10. Vaccination uptake – the process of obtaining a vaccination.
Logic Model
This logic model represents relationships starting with inputs, outputs, and
outcomes. Short term outcomes include increasing HPV and HPV vaccine knowledge in
college students, assessing pre and post education HPV and HPV vaccine knowledge.
Medium term outcomes include an increase of HPV and HPV vaccine knowledge in
students and the general public. A long-term outcome of this project is increasing HPV
vaccine uptake. There are assumptions and external factors that contribute to the success
of this project. Assumptions include students gaining knowledge from the education and
the students taking the pre and posttest to the best of their ability. External factors include
availability of the vaccine, cost of the vaccine, and personal beliefs and attitudes.
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Figure 1:
Logic Model
Outputs

Outcomes – Impact

Inputs
Activities

1. Education
given by
power point
presentation.
2. DNP student
3. IRB
approval

Pre and Post
HPV
knowledge
assessment
HPV/HPV
vaccine
education
presentation

Participation

Fall 2019
health
promotion
undergraduate
students at
Pittsburg
State
University

4. Fall 2019
health
promotion
undergraduate
students at
Pittsburg State
University

Assumptions
Students will gain knowledge after the
presentation and HPV vaccination rates
will increase.
Students will take the assessment to the
best of their ability.

Short

Medium

Long

There will
be an
increase in
HPV and
HPV
vaccine
knowledge
after the
educational
presentation.

There
will be
an
increase
of HPV
and
HPV
vaccine
knowledge in
students
and the
general
public.

There
will be
an
increase
of the
HPV
vaccine
uptake.

External Factors
Personal beliefs and attitudes
Cost
Availability
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Summary
HPV is a very common virus that most people contract throughout their lifetime.
The number of people that remain unvaccinated in Kansas from HPV remains low, even
though research shows the vaccine provides many benefits. This education focuses on
providing education to Pittsburg State University undergraduate students from many
majors including nursing and other health related majors. This knowledge will contribute
to the knowledge of HPV in hopes to raise the HPV vaccination rate. Chapter II provides
a literature review on HPV knowledge and the HPV vaccine.
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CHAPTER II

Literature Review

Vaccines are one of the greatest defenses from deadly diseases. Vaccines have
evolved over time and in recent years vaccines that protect against cancer have been
developed. This literature review will focus on and describe the many different factors
that lead to compliance of the two or three dose HPV vaccination that is obtained by the
public from age 11 through 26.
Purpose
The purpose of this literature review is to analyze barriers that contribute to
omitting the HPV vaccination and possible implications for the public and healthcare
professionals including the advanced practice registered nurse. This literature review will
examine what barriers; perceived or actual, prevent young adults and children from
getting recommended vaccinations. Interventions that could be used to increase the rate
of vaccinated young adults will be reviewed and how primary care providers can
implement these interventions. Whether providers adequately communicate
immunization education and benefits with patients, parents, and guardians will be
analyzed. Factors that affect the status of a child being vaccinated include: lack of
information and education, beliefs, and lack of access or financial means.
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Method
An electronic search was conducted using the database CINAHL Plus with full
text to identify studies published between 2014-present. Articles researching the HPV
vaccine have been published for over 13 years but for current information, the search was
limited to the last five years. Search terms used were “HPV vaccine”. Only full-text,
English articles in the geographic region of the United States was involved in the search.
Initially searching for “HPV vaccine” with the above indications resulting in 146 results.
Practice Change Guidelines
Selection of Best Practice Guidelines
The General Best Practice Guidelines for Immunization was established by the
Advisory Committee on Immunization Practices (ACIP). There are 10 documents that
include specific recommendations of vaccines in this clinical practice guideline (CPG).
This guideline is updated every three to five years by both review and analysis of current
scientific data and expert opinions of different health-care providers and officials from
public health which are members of the General Recommendations Work Group
(GRWG). Several groups of healthcare are professionals involved including family
practice, pediatrics, and pharmacy. To appraise the quality of this CPG the AGREE II
instrument was used (AGREE Next Steps Consortium, 2013). The Grading of
Recommendations Assessment Development and Evaluation (GRADE) system was used
to rate the CPG. This CPG was found to have high quality of evidence and research
including key evidence and guidelines to defend the strong strength of the
recommendations. The 10 documents contained guidelines for all developed vaccines
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recommended by the CDC, this paper will focus on the guidelines pertaining to the HPV
vaccine.
Table 2:
Summary of General Best Practice Guidelines for Immunizations
Document

Vaccine

Recommended

Minimum

Recommended

Minimum

Three –

& dose

age for this

age for this

interval to

interval to next

timing and

number

dose

dose

next dose

dose

spacing of
immunebiologics

HPV Two Dose Series (If starting the vaccine at age 9 through
14 years old)
HPV –

11-12 years

9 years

6 months

5 months

11-12 years

9 years + 5

-

-

1
HPV –
2

months

HPV Three Dose Series (Typically given at age 15 and older)
HPV –

11-12 years

9 years

1-2 months

4 weeks

11-12 years

9 years (+4

4 months

12 weeks

-

-

1
HPV –
2

weeks)

HPV –

11-12 years

9 years (+5

3

(+6 months)

months)

(Quality of Evidence – High, Strength of Recommendation -Strong)

Document

1. Contraindications include any severe allergic reaction or

4–

anaphylaxis after a previous dose of the HPV vaccine or to

Contraindi-

any vaccine component, which includes yeast.

15

cations

and

2. Conditions commonly mistaken as contraindications or

precaution

precautions for all general vaccines, including HPV, and

s

this includes any acute mild illness that does or doesn’t
produce a fever, patient does not have a previous physical
exam in a well-appearing person, if a person is on
antibiotics, mending phase of an illness, recurrent exposure
to an infectious disease, history of other non-vaccine
allergies, penicillin allergy.
3. Common mistaken contraindications and precautions
specific for the HPV vaccine include: previous abnormal
papanicolaou test, breast feeding, history of genital warts,
a current HPV infection, or immunosuppressed.
(Quality of Evidence – High, Strength of Recommendation,
Strong)

Document

1. If an adverse reaction occurs with a vaccine this is

five –

reported in the Vaccine Adverse Event Reporting

preventing

System (VAERS). In 2005, the HPV, MenACWY, and

and

Tdap vaccines were flagged in this system, due to the

managing

vaccines causing syncope. If syncope occurred these

adverse

adolescents were at in increased risk for injuries due to

reactions

the syncope including skull fractures and cerebral
hemorrhages. Between January 1, 2005 to July 31, 2007
463 VAERS reports were issued due to syncope and 41
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of those obtained secondary injuries. Approximately
76% of those reports were categorized as adolescents.
Within 15 minutes of vaccine administration 80% of the
syncope episodes happened among all age groups. This
has encouraged providers to be proactive when giving
vaccines to prevent injuries due to dizziness or syncope.
When giving the vaccine the patient should be sitting or
lying down and the patient should be observed for 15
minutes after administration, if symptoms develop the
patient should be kept until all symptoms resolve.
2. Serious allergic reactions are rare occurring one per
million dose for many different vaccines. Airway
management equipment and epinephrine should be
available to be used immediately if a reaction occurs.
The best practice to avoid allergic reactions is to obtain
a thorough history.
(Quality of Evidence – High, Strength of
Recommendation, Strong)
Document

1. The HPV vaccine is a 0.5 ml dose and to be given

six –

intramuscularly.

Vaccine

(Quality of Evidence – High, Strength of Recommendation,

admin-

Strong)

istration
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Document

1. The HPV vaccine is to be stored at a temperature of 2 -8

seven –

degrees Celsius, the vaccine is not to be frozen and is not

storage

to be diluted.

and

(Quality of Evidence – High, Strength of Recommendation,

handling

Strong)

of
immunobio
-logics

Document

1. Research does not recommend pregnant women receive the

nine –

vaccine even though it is not a live virus and no evidence

Special

exists showing the vaccine to be harmful to the fetus.

situations

(Quality of Evidence – Moderate, Strength of
Recommendation, Strong)

Document

1. The HPV vaccine is said to be critical for adolescents and

eleven –

young adults in general due to a higher risk or increasing

Vaccinat-

risk of the HPV infection. Vaccination of the HPV is

ion

essential in preventing disease.

programs

2. To improve vaccination rates among children, adolescents,
and adults, recommendations of interventions were
researched. Community education alone had insufficient
evidence on whether it was effective and community-based
interventions implemented in combination was
recommended to increase vaccine rates.
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(Quality of Evidence – High, Strength of Recommendation,
Strong)
Reproduced from Ezeanolue, Harriman, Hunter, Kroger, & Pellegrini, C.,
2017.
Lack of Information
Lack of information can be a contributing factor to not receiving the HPV
vaccine. Research has identified that the lack of information regarding HPV and
the HPV vaccine exist. College-aged students might already know what HPV and
the HPV vaccine, but others may not recognize these topics.
According to Lai, et al., (2016) a 21-item survey was used to assess 228
African American, African refugee, Hispanic/Latino, American Indian, and
Native American from community organizations of their knowledge of the HPV
vaccine. The majority of the respondents were age 35-50, female, and married, or
living as married. Almost 67% of the surveys participants were immigrants and
over half had health insurance. Approximately 46.5% of the respondents had
heard of the HPV vaccine. The study found that people less acculturated were
more likely to learn about HPV through personal networks, such as friends,
family, and church. Participants born in the US were more likely to learn about
the HPV vaccine through media such as social networks, billboards, and
television. The study found that healthcare system sources were the most
preferred source of HPV information. The participant had an increased accuracy
of knowledge of the HPV vaccine if the healthcare provider educated the patient
on the HPV vaccine. The study stressed the need for more culturally aware HPV
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education that could provide an increased uptake of the HPV vaccine (Lai, et al. ,
2016).
According to Macarthur (2017), a study of 755 college students from a
large midwestern university were asked about their health beliefs, and if this
related to whether they had received the HPV vaccine. The study was conducted
between November 2012 and January 2013. The study concluded tha t the belief
in one’s health care provider is directly linked to an uptake in the intentions of
the HPV vaccine
Lack of Education
Education regarding HPV and the HPV vaccine can be overwhelming.
Health care providers are responsible for providing accurate education to
patients. Studies indicate that a health care providers recommendation influences
the HPV vaccine uptake.
A qualitative study conducted by Ogunbajo, Hansen, Noth, Okoloko, &
Niccolai, (2016) researched knowledge of HPV and the HPV vaccine from the
parents and legal guardians of children aged 10-18 from lower incomes and
ethnic minorities. Many participants felt the HPV vaccine was no diff erent than
any other vaccine in that they prevent disease, was administered the same, and
believe in the recommendation of the health care provider. The fact that HPV
prevents cancer, which was viewed as a serious disease, was one of the greatest
benefits. Mixed opinions were stated from the parents due to the mode of sexual
transmission for HPV. Most guardians and/or parents had a positive view of the
HPV vaccine. Ogunhaio et al. (2016) stated strategies for increasing the uptake
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of the HPV vaccine in this age group is bundling the vaccine with the TDAP and
meningitis vaccine or school entry requirements.
A study conducted by Kornides, Calo, Heisler-MacKinnon, and Gilkey
(2017), studied U.S. providers and clinic staff experiences of the 9 -valent HPV
vaccine, which is the current HPV vaccine administered. In this study of 211
participants the quadrivalent vaccine was used. When comparing the previous
quadrivalent vaccine to the 9-valent vaccine providers stated they would strongly
recommend (66%) or more strongly (33%) recommend the 9-valent over the
quadrivalent. At least 61% of the study reported no concerns with the up -to-date
HPV vaccine but 29% reported parental hesitancy, 17% insurance coverage
issues, and 10% other issues. This study reported provider recommendation was
the most important facilitator in obtaining the HPV vaccine. Parental concerns
were not investigated which could be used by staff to educate further. Education
of terminology was reviewed with providers regarding vaccines to not use words
such as “new” with patients, for example, there is a new vaccine for HPV.
A survey of parents of adolescents regarding parental willingness of the
HPV vaccine administration was conducted by Erves, Mayo-Gamble, Hull, Duke,
and Miller (2017). In the study 47% of parents were willing to let their
adolescent participate in the HPV vaccine clinical trial. There was a total of
30.7% African American and 48.3% Caucasian asked to participate. In total
African Americans had a lower awareness of the HPV vaccine b ut no lower
intentions to get the HPV vaccine. The child’s age, perceived advantages of the
HPV vaccine, and trust in the medical researchers and being able to understand
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the clinical trial information with ease was positively associated with parental
willingness. Education was found to have a positive impact on the uptake of the
HPV vaccine in this study.
An observational study conducted by Wilson, et al. (2016) examined
factors related to HPV vaccine uptake of 325 18-26-year-old females in Utah.
The results of the study stated 204 (62.8%) had received a single HPV vaccine:
of those that received at least one dose of the HPV vaccine, 159 (48.9%)
completed the HPV vaccine series. Lower age, not currently married, not
practicing an organized religion, education on how HPV spreads, awareness of
the relationship between HPV and cervical cancer, confidence in vaccine
prevention, doctor recommendation and how influential the doctor’s
recommendation was were all factors contributed to completion of the HPV
vaccine series as well.
Beliefs
The HPV vaccine can have a stigma due to HPV being caused by
unprotected, vaginal, anal, and oral sex. Even if intercourse only occurs with one
person, the other person may have had other contacts before which can put
anyone at risk that has unprotected sex with this person. Males are not screened
for HPV and many times have no symptoms of a current HPV infection.
According to Franco, Mazzucca, Padek, and Brownson (2019) the highest
completion of the HPV vaccine series is the District of Columbia with 62% and
Rhode Island with 70.8%. The states with the lowest completion rates are Texas,
Utah, South Carolina, Wyoming, and Mississippi. The states with higher non -
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completion rates are known to be more conservative and religious states than
those with higher completion rates. In these states there were no stricter
education policies or vaccine exemptions. The study included 20,495 adolescents
from all 50 United States. The study concluded that many factors contribute to
the HPV vaccine uptake and completion including political beliefs, education
through sex education, religion, and gender. The clinic is the most important
location and the preferred source for information on deciding to complete the
HPV vaccines. The television was the second preferred source, followed by
schools and pamphlets.
A study focusing on factors associated with school nurses’ HPV vaccine
attitudes for school-aged youth by Rosen, DiClemente, Shepard, Wilson, and
Fehr (2017) had 413 participants from the National Association of School
Nurses’ membership that completed a web-based survey. The study revealed that
positive attitudes toward the HPV vaccine is associated with a higher HPV and
HPV vaccine knowledge. This study reiterated additional education to be given
about the HPV vaccine and HPV so that these nurses could relay the accurate
information to parents to increase the uptake of the HPV vaccine.
Lack of Access
Access to the HPV vaccine can be an issue due to cost and availability.
The HPV vaccine can be expensive without insurance, which can be a barrier to
vaccination. If the patient does not have transportation or time to receive the
vaccine these can be factors as well.
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A qualitative study conducted by Roncancio, et. al., (2016) of 51 in-depth
interviews of Hispanic mothers of adolescents of the product, price, place, and
promotion of the HPV vaccine. The study found that vaccine reminders, the fact
that the HPV vaccine prevents illness and disease were the factors in those that
completed the vaccine series. Those mothers that children had completed the
vaccine series had no barriers. Mothers whose children had received the first
dose of the HPV vaccine but not the 2 nd or 3 rd dose stated cost and lack of health
insurance as barriers.
A study conducted by Britt and Britt (2016) looked at the rural healthcare
needs related to the HPV vaccine. The study examined students from a rural and
medically underserved campus with 327 participants. The HPV vaccine uptake
was as follows: 48.3% no vaccine uptake, 38.8% reports one immunization, 8.4%
reports two shots, and 4.5% reporting completion of the HPV vaccine series. The
study found no significant relationship between, intent, gender, beliefs, and
attitudes of the HPV vaccine. Gender was a predictor of vaccine uptake, the
research recommends that males receive education that state they can receive the
HPV vaccine, as it is known females can receive the HPV vaccine. The intent t o
complete the vaccine series is most linked to a doctor’s recommendation.
Barriers stated in this study were perceived susceptibility of HPV and cost.
Increased vaccination rates were a result from positive attitudes of the HPV
vaccine. The study recommended rural college campuses need to be targeted to
complete the HPV vaccine. Creating a positive attitude of the HPV vaccine can
motivate students to receive the HPV vaccine.
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Implications
There is a limited amount of research conducted in the United Stat es
specifically related to the HPV vaccine. More research should be conducted on
these barriers to examine them further. Several of the research articles found
only used a sample of females. The HPV vaccine pertains to all genders. No
significant conflicting data was found. Many of the articles stressed belief in the
health care providers recommendation, education about HPV and the HPV
vaccine, and access to the vaccine.
Summary
Vaccination compliance is a gray area to the public. It is important for
healthcare providers to do research and relay that information to patients.
Existence of vaccine preventable diseases and cancers prove that there is still
room for improvement. Assessing for vaccine compliance is important at every
visit with every patient.
There are many questions that are not answered from the literature review
including what the views of HPV in Kansas are, what their concerns are for
vaccinating with the HPV vaccine, and if these views differ in every state? A
study being conducted of assessing HPV vaccine uptake, HPV vaccine, and HPV
education at a rural college campus and what variables can be changed to
improve vaccination rates could benefit the public.
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CHAPTER III

Project Design

This chapter will review the design for this scholarly project. The sample group,
instrument used, and statistical analysis will be discussed. A two-part study was
performed to evaluate whether there will be an increase in knowledge post-education of
HPV. A quantitative study was used to evaluate knowledge with a pretest and posttest.
Several tests were used to evaluate responses including an independent sample t-test, a
paired sample t-test, and a mean and standard deviations. Quantitative data generalizes
numerical data across a group of people that can help explain an occurrence. The research
ultimately supports or rejects the occurrence. This data can be presented into graphs and
tables (McLeod, 2019).
A descriptive research approach was used to study knowledge of HPV and the
HPV vaccine among college students. The study educated 58 students on facts and
evidence-based clinical practice guidelines regarding HPV and the HPV vaccine. The
education was provided in the Pittsburg State University Fall 2019 Health Promotion
class. The pretest included demographics, HPV experiences of study participants, and a
questionnaire with 18 true/false questions.
Research of HPV and the HPV vaccine was obtained and studied by the
researcher. The study was designed by utilizing research of the topic, the pretest was
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developed from a previous study conducted by Salima Kasymova, Sayward Harrison, &
Caroline Pasca, (2019), based on research found and objectives of this study. Approval
was given to use previous use tool by the developer, Sayward Harrison. A pretest and
posttest was administered in this study that was used from a previous study conducted by
Salima Kasymova, Sayward Harrison, and Caroline Pascal and education was presented
to the audience in the form of a PowerPoint. The pretest was complete prior to the
educational presentation and the posttest was completed after the educational
presentation. Analysis of the data obtained was reviewed by the researcher. This
researcher and statistician ultimately interpreted the data collected. The data interpreted is
available in this project in the following chapters. Presented below is the study design.
Figure 2:
Study Design

Research
Questions
•Research of topic
•Approval to use
instrument

Educational
Presentation

Test Scores
•Anaylsis

Interpretation
of Data

•Pretest
•Posttest

An educational presentation was designed for college students enrolled in the
Health Promotion class. The study evaluated whether an increase of knowledge will be
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obtained after evidence-based practice research was presented to the audience. The
knowledge presented would expand on current knowledge with evidence-based practice.
The study focused on the following research questions:
1. What are the demographics (gender and age) of the respondents?
2. Will students have heard of the HPV vaccine pre-education?
3. Will students have heard of HPV pre-education?
4. What is the respondent’s HPV knowledge pre-education?
5. Has a healthcare provider recommended the HPV vaccine to the respondent?
6. Has the respondent received at least one dose of the HPV vaccine series?
7. What is the respondent’s HPV knowledge post-education?
8. Did education increase the knowledge of HPV post-education?
Settings and Participants
The setting of this study was at the Pittsburg State University Irene Ransom
Bradley School of Nursing lecture hall. The educational presentation was conducted on
December 4th, 2019. The population of this study included students enrolled in the
Health Promotion class in the Fall of 2019 at Pittsburg State University. All participants
were eligible to participate in the pretest and posttest and the presentation, consent was
implied with the completion of the pretest. The participants were all over the age of 18.
Recruitment
The target population recruited for this presentation and survey is the Fall
2019 Health Promotion class at Pittsburg State University. This class consisted
of 58 students includes pre-nursing, nursing, and health majors. The presentation
was approximately 20 minutes in length, not including the pretest and posttest.
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Participation was voluntary in nature; students were given the opportunity to
leave class before the presentation began. No compensation, or extra credit was
provided to the participants. Full participation in this study includ e completion
of the pretest and posttest and being present for the educational presentation.
Inclusion/Exclusion Criteria
Inclusion criteria for the pretest and posttest and presentation included all
students enrolled in the Health Promotion class. The participant must be over the
age 18. No other inclusion was used in this study. The specific exclusions for
this study include being under the age of 18, not enrolled in the Pittsburg State
University Health Promotion class, and not giving consent.
Protection of Human Subjects
The checklist for human subjects was reviewed by the researcher and it was
deemed that the study followed the Pittsburg State University human subjects and
departmental guidelines for an exempt study. The process of the study was reviewed by
the Human Subject Committee at Pittsburg State University. The population for the
educational presentation was adult students over the age 18. The population does not
contain any children, prisoners, or any specific people of race, religion, or ethnicity.
There was no techniques that caused harassment or discomfort or deception of
participants. Confidentiality was maintained throughout the study through numbering the
pretest and posttest along with specific questions answered at the beginning of the pretest
and posttest. There were no risks involved with participation in this scholarly project.
Responses of this scholarly project was not disclosed outside of the scholarly project that
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could place them at risk of civil or criminal liability or have any damage to their
reputation, employability, or school standing.
Data was obtained from participants volunteering for the study. Completion of the
pretest and posttest ensured consent for the study. Confidentiality was maintained
throughout the study and the information obtained include four identifying factors of the
participants: the first initial of mother’s name, first initial of Mother’s maiden name, first
initial of the town they were born in, and first initial of their middle name, the surveys
were numbered. After the surveys were complete, they were placed in a locked box only
accessible to the researcher. At completion of the scholarly project the test were
shredded.
Ethical Considerations
There are few ethical considerations for this study. This descriptive study design
has a pretest and posttest. Any ethical considerations focused around the test
development and the answers provided. Consistent anonymity is the first ethical concern.
The information obtained from the surveys remained confidential and was stored without
identifiers so participants cannot be identified by any way or anyone. Participants
truthfully answering surveys is the second ethical concern. Data can be skewed if
someone intentionally provides false data. The test used is from a previous research
project and validity and reliability has been proven.
Instrument
The pretest and posttests were conducted by using pen and paper by the
participants to gather quantitative data. There was three sections of the survey. The first
section assessed demographic data. The second section assessed HPV experiences. The
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third section assessed HPV knowledge. The posttest included only the third section along
with a section that assessed impact of the education provided. The test contained yes/no
and true/false responses. The pretest included demographics, HPV experiences, and 18
HPV knowledge questions. The posttest included the 18 HPV knowledge questions and a
question that evaluates the impact of the education provided. The tool used is consistent
with evidence-based practice.
Content Validity
The survey tool accurately reflects students’ knowledge of evidence-based
practice guidelines of HPV and the HPV vaccine. The tool is from a previous peerreviewed research study by Salima Kasymova, Sayward Harrison, and Caroline Pascal
(2019). This tool yielded a strong internal consistency (=.79). Contact was made with
Dr. Sayward Harrison regarding reuse of the HPV survey and this was granted. Dr. Greg
Belcher, Ph. D., Director of the Kansas Center for Career and Technical Education at
Pittsburg State University, a committee member of this project reviewed validity of the
survey.
Operational Definitions
The following operational definitions are used in the purpose of this project:
1. Human papillomavirus (HPV) – A kind of virus that can cause abnormal
tissue growth and other changes to cells. Long term infection with certain
types of human papillomavirus or HPV can cause cervical cancer and can
play a role in some other types of cancer, such as anal, vaginal, vulvar,
penile, and oropharyngeal (National Cancer Institute, (n.d.).
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2. Immunization – the process of obtaining protection though vaccination
from diseases, also used interchangeably with vaccination, inoculation, or
vaccination uptake (CDC, 2018e)
3. Vaccination – receiving a vaccine that will allow the body to gain
immunity against a specific disease; inoculation
4. Vaccine – “A product that stimulates a person’s immune system to
produce immunity to a specific disease, protecting the person from that
disease. Vaccines are usually administered through needle injections but
can also be administered by mouth or sprayed into the nose (CDC,
2018e).”
Procedure
This project contained an educational presentation, a pretest, and a posttest. The
participants were present for class in the Fall 2019 Health Promotion class at Pittsburg
State University. Once seated the study was explained and students had the opportunity to
dismiss themselves if desired. The participants was then handed a packet. The packet
contained both the pretest and the posttest. The participants were instructed to not open
the envelope until instructed, until the presentation was explained and questions
answered. The participants were instructed to take the pretest out of the packet. The
pretest contained demographics, HPV experiences, and HPV knowledge test. The pretest
was completed and placed in the locked box, then the educational PowerPoint was
presented to the class. The presentation was explained, and questions were answered. The
educational program was presented and lasted approximately 20 minutes. There was an
opportunity for participants to ask questions. The participants then removed the posttest
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from the packet. The posttest contained the same HPV knowledge survey and possible
future actions from the presentation. Once completed the posttest was secured in the
locked box. The surveys were matched by number and specific responses on the surveys
and data was logged into SPSS. All data was reviewed and is accurate to the researcher.
Data Collection
The pretest contained demographic data. This ensured inclusion of the group and
characterized the participant by gender. The data was collected kept confidential online
and only accessed by the researcher. The results of the project is published in Chapter IV
of the project without any identifying data. At the end of the project the tests were
shredded.
The data was entered and analyzed using SPSS and formulations calculated. A
probability level of p<0.05 is considered statistically significant. T-tests were conducted
on the results of the pretest and posttest. A comparison of the pretest and posttest was
conducted.
Outcome Data
Based on the analysis of the pretest and posttest the following outcomes were
generated by the SPSS program for the following research questions.
1. What are the demographics (gender and age) of the respondents?
2. Will students have heard of the HPV vaccine pre-education?
3. Will students have heard of HPV pre-education?
4. What is the respondent’s HPV knowledge pre-education?
5. Has a healthcare provider recommended the HPV vaccine to the respondent?
6. Has the respondent received at least one dose of the HPV vaccine series?

33

7. What is the respondent’s HPV knowledge post-education?
8. Did education increase the knowledge of HPV post-education?
Outcomes
Evaluation measures linked to objectives. Objectives in the logic model was
used for evaluation measures. The project contained an educational presentation with a
pretest and posttest to evaluate knowledge of evidence-based research of HPV and the
HPV vaccine. The outcomes that was evaluated include increasing HPV and HPV
vaccine knowledge, assessing pretest and posttest data, and evaluating if data encouraged
vaccine uptake if the participant had not received the HPV vaccine. If correct answers are
answered on the posttest a positive outcome will be achieved. Short-term outcomes that
was accomplished include increased knowledge of HPV and the HPV vaccine after the
education presentation. Medium-term outcomes include an increase of vaccine
knowledge in students and the general public. Long-term outcomes include that there will
be increased rates of HPV vaccination, which will take years to evaluate. Further research
should be conducted at that time.
The posttest was given directly after the presentation to keep the information
relevant and no other information was obtained by the participants. The data obtained
from the pretest and posttest was assessed to evaluate if an increase of knowledge
occurred.
Instrument Linked to Measures and Objectives. This measurement tool
included a pretest and posttest after an educational presentation over evidence-based
research of HPV and the HPV vaccine. The instrument included an 18 HPV knowledge
questionnaire. Demographic questions were on the pretest only. The posttest included the
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same questions as the pretest. A total score of correct answers was tabulated for each
participant. The test had a variety of questions with the HPV knowledge questionnaire
being all true or false. Spontaneous responses were not allowed on the test. The test
questions validated evidence-based research knowledge of HPV and the HPV vaccine.
The table below represents questions answered and intended outcomes of the project.
Table 3:
Objectives, Measurements, and Outcomes
Objectives

Measurement

Outcome

Analysis

Participants will

Participants will

Participants will

t-test

provide

provide basic

choose accurate

demographics.

demographics to

demographics.

ensure inclusion of
the study.
Participants will

Participants will

Participants will

Mean and standard

have heard of the

submit if they have

correctly answer if

deviation

HPV vaccine pre-

heard of the HPV

they have heard of

education.

vaccine pre-

the HPV vaccine

education.

pre-education.

Participants will

Participants will

Participants will

Mean and standard

have heard of HPV

submit if they have

correctly answer if

deviation

pre-education.

heard of the HPV

they have heard of

pre-education.

the HPV preeducation.
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Participants will

Participants will

Participants will

have knowledge of

submit correct

appropriately

HPV pre-education.

answers on the

identify correct

pretest, pre-

answers in the HPV

education.

questionnaire,

t-test

pretest.
Participant will

Participants will

Participants will

Mean and standard

have had a health

have an increase of

submit whether a

deviation

care provider

health care provider

healthcare provider

recommend the

recommend the

has recommended

HPV vaccine.

HPV vaccine.

the HPV vaccine.

Participant will

Participants will

Participants will

have received once

receive the HPV

submit whether that

dose of the HPV

vaccine.

have received the

vaccine.

T-test

HPV vaccine.

Participants will

Participants will

Participants will

have knowledge of

have an increase of

correctly answer

HPV post

HPV knowledge

questions on the

education.

post education.

posttest.

Participants

Participants will

Participants will

Independent

knowledge of HPV

increase their

submit correct

samples t-test

will increase post

knowledge of HPV

answers on the post

education.

post education by

test questionnaire.
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t-test

correct responses
on the post test.

Methods of Analysis for Measurement
To analyze the data collected the data was transferred into SPSS. The probability
level accepted is p<0.05. If less than 0.05 occurs then the outcome occurred by chance
and not because of the educational presentation. Results occurring as a result of the
education indicated a 95% confidence interval. To compare the pretest and posttest t-tests
were used.
Each question was worth one point. The pretest and posttest was used to evaluate
knowledge gained from the educational presentation of evidence-based research of HPV
and the HPV vaccine. The HPV knowledge questions were all true/false answers.
Sustainability
There is no specific criteria for sustainability. An effective way to increase
knowledge of HPV and the HPV vaccine is through education. Sustainability can be
ensured by education of evidence-based research of HPV and the HPV vaccine to health
care providers. There are several different avenues that education can be provided to the
public including through public schools, public health fairs, and through local doctors’
offices. Planning and implementation will ensure sustainability of evidence-based
research of HPV and the HPV vaccine.
Summary
Evidence based research of the HPV and the HPV vaccine was presented as an
educational presentation to a health promotion class of college students. A pretest was
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completed prior to the education and a posttest was be obtained after the education. The
survey included a questionnaire with 18 true/false questions. The results of this project
are presented in Chapter IV.
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CHAPTER IV

Findings

A descriptive research design was utilized in this scholarly project. This data was
collected to determine if there would be an increase in knowledge about HPV and the
HPV vaccine in college students in the Health Promotion class at Pittsburg State
University after the students were provided with an educational PowerPoint lecture over
HPV and the HPV vaccine. The data in this scholarly project was collected by a pretest,
followed by an informative PowerPoint lecture concerning HPV and the HPV vaccine
education and the posttest was collected. The sample included 58 students. The pretest
contained demographic information and a HPV questionnaire of 18 questions. An
educational PowerPoint was then presented. A posttest was them completed by the
students that included the same 18 HPV questionnaire, along with inquiring if they intent
to receive the HPV vaccination post education. The pretest contained demographic
questions including gender, if they have ever heard of HPV and the HPV vaccine, and if a
provider has ever recommended the HPV vaccine to them. The test also asked if they
have obtained the HPV vaccine and 18 questions about HPV and the HPV vaccine.
Demographic Data
The demographic data collected from respondents included gender, of the
respondents with 6.9% (n=4) male and 93.1% (n=54) were female. Most of the
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respondents were female (93.1%). The study found 100% of the participants had heard of
the HPV vaccine pre-education (n=58). Almost all of the participants have heard of HPV
pre-education, 96.6% of students had heard of HPV (n=56) and 3.4% of students had not
heard of HPV pre-education (n=2). Of the participants, 70.7% had the HPV vaccine
recommended to them (n=41), 27.6% had not had the HPV vaccine recommended to
them (n=16), and 1.7% of participants did not know if they have had the HPV vaccine
recommended to them (n=1). The participants were asked if they had received at least
one dose of the HPV vaccine series, 75.9% of students stated they had received at least
one dose (n=44), 15.5% of students had not received the HPV vaccine (n=9), and 8.5% of
respondents did not know if they had received the HPV vaccine (n=5).
Table 4:
Gender of Participants
Frequency
Male
Female
Total

4
54
58

Percent
6.9
93.1
100.0

Frequency
58

Percent
100.0

Table 5:
Has the Respondent Ever Heard of the HPV vaccine?

Yes
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Table 6:
Ever Heard of HPV Pre-education?
Frequency
56
2
58

Yes
No
Total

Percent
96.6
3.4
100.0

Table 7:
Has a Healthcare Provider Recommended the HPV Vaccine to the Respondent?
Frequency
41
16
1
58

Yes
No
Don’t Know
Total

Percent
70.7
27.6
1.7
100.0

Table 8:
Has the Respondent Received at Least One Dose of the HPV Vaccine Series?
Frequency
44
9
5
58

Yes
No
Don’t Know
Total

Percent
75.9
15.5
8.6
100.0

Pretest and Posttest
All participants were given a pretest prior to the education and posttest following
the education. The tests were given to the participants in a large yellow envelope and
grouped by a number code in the right-hand corner along with 4 anonymous answers at
the top of each test. Both tests contained the same 18 HPV questionnaire that were true,
false and focused on HPV education established by evidence-based-practices. The HPV
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questionnaire was from a previous study conducted in South Carolina by Salima
Kasymova, Sayward E Harrison, and Caroline Pascal in 2019. For each correct answer on
the HPV questionnaire a point was received, if a person answered every question correct,
they would receive 18 points.
Results of the Study
The study concluded with statistical significance (p<0.05) that the education
provided did increase the knowledge of the students with evidence-based facts on HPV.
The posttest scores were higher after the education was presented. All pretest and posttest
were completed entirely. The mean score of the pretest was 11.79 questions correct out of
18, with a standard deviation of 2.634. The mean score of the posttest was 16.47
questions out of 18, with a standard deviation of 1.513. This concluded that there was a
difference between knowledge of HPV on the pretest and posttest. All participants had an
increase in posttest sores after the education was presented (n=58). After the education
there were seven participants (50%) that reported they intended to receive the HPV
vaccination.

Table 9:
HPV Knowledge on Pretest and Posttest
Pretest Score
11.79
2.634

Mean
Std. Deviation
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Posttest score
16.47
1.513

Table 10:
The Difference in Knowledge of HPV on the Pretest and Posttest

Pair 1

Pretest Score
Posttest score

Mean
11.79

SD
2.634

16.47

1.513

Paired Differences
Std. Error
Mean
SD
Mean
Pair Pretest Score 1
Posttest score

-4.672

2.793

.367

t

N
58
58
df

-12.739 57

Sig. (2tailed)

.000

Individual Comparison of Pretest and Posttest
On the pretest the most missed question was question number six, most genital
infections do not clear up on their own (false) with 79.3 percent of the students choosing
the incorrect answer of true (n=46). Followed by question four, there is a test to
commonly test males for HPV (false), and question 10, the HPV infection can cause
genital herpes (false). Both of these questions had 72.4% of the students answer them
incorrectly by stating they were false when in fact they are true (n=42). Question 18,
nearly all sexually active men and women will contract HPV at some point (true), had
68.9% of students answer this question incorrectly stating that it was false (n=40). The
questions that had the most answered correctly was question 11, certain types of HPV can
lead to cervical cancer in women (true), and question 12, HPV can lay dormant in the
body for years without symptoms (true) with 98.2% of students answering these two
questions correctly (n=1).
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On the posttest there are several questions with 100% of students answering the
question correctly, questions 1, 5, 8, 11, 12, and 13 (n=0). Question one is, HPV is a
sexually transmitted infection (true), question five is an abnormal Pap smear may indicate
that a woman has HPV (true), question eight is HPV is not a very common virus (false),
question 11 is certain types of HPV can lead to cervical cancer in women (true), question
12 is HPV can lay dormant in the body for years without symptoms (true), and question
13, a person’s chances of getting HPV increase with the number of sexual partners they
have (true). The most missed question on the posttest was question 15, genital warts can
cause cervical cancer (false), with 37.9% of students answering this question incorrectly
(n=22).
Question four, there is a screening that is commonly used to test males for HPV
(false) and question 18 (nearly all sexually active men and women will contract HPV at
some point (true) had the biggest improvement of correct answers from the pretest to the
posttest, with a 35 point difference on question four and a 34 point difference on question
18.

44

Figure 3:
Comparison of Incorrect Answers

Comparison of Incorrect Answers
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Summary
Chapter IV reviewed the statistical analysis of this project. A positive outcome of
this project includes an increase knowledge about HPV and the HPV vaccine after the
education was presented to this group of participants. Before the education was presented
participants answered approximately 12 of the questions right out of 18 and after the
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education the score increased to 16, showing improvement. This study concluded that
even though most students were recommended the HPV vaccine there was still a
knowledge gap about HPV and the HPV vaccine. The findings of this study confirm the
need for more education about HPV and the HPV vaccine amongst college students to
help prevent HPV and HPV related diseases.
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CHAPTER V

Summary, Conclusions, Recommendations

This study included an educational presentation about HPV and the HPV vaccine
following evidence-based facts and guidelines to evaluate overall knowledge of HPV.
The study assessed students’ knowledge after an educational presentation. A pretest was
taken before any education and a posttest was given immediately after the education was
presented. The project also evaluated if students had received the HPV vaccine or have
had this vaccine recommended to them by a provider.
Relationships of Outcomes to Research
This study found that 75.9% of the participants had at least one dose of the HPV
vaccine. This is still below the Healthy People 2020 goal of 80% of the public being
vaccinated with the HPV vaccine. In a previous study by Salima Kasymova, Sayward
Harrison, and Caroline Pascal (2019) the rate of HPV vaccination was 64.1% and 72.7%
of participants reported a provider recommended the HPV vaccine. In this study, 70.7%
of the participants reported a provider recommended the HPV vaccine to them. This is an
opposite finding of this study that had a lower number of vaccinated participants and a
higher number that had had the HPV vaccine recommended to them. More respondents in
this project obtained this vaccine without recommendation from a provider than the
previous study. The mean total score of the previous study was 8.9 on the pretest with a
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standard deviation of 3.7. This study had a mean total score of 11.79 and a standard
deviation of 2.634 on the pretest. One of the most missed questions on both of these
studies was whether there is a screening commonly used to treat males and if HPV
infections generally clear up on their own. There was also confusion on this study and the
previous study on the distinction of HPV and genital herpes. Both studies found the
majority of participants were aware of HPV. This study confirmed that more education is
needed on HPV to the public including college students.
Observations
Many different observations can be made from the data gathered on the pretest
and posttest. The information gathered can be used to compare with previous studies and
research. Even though one of the previous studies was done with a larger sample, similar
data is found in this smaller study. A knowledge gap exists of HPV and the HPV vaccine
with an average of the participants missing at least seven out of 18 questions. Even
though the number of participants that reported obtaining at least one dose of the HPV
vaccine is below the healthy people 2020 goal it was higher than previous studies at
75.9%. The number of participants that have had the HPV vaccine recommended to them
was less than previous studies. This could possibly mean the participant did not have a
providers recommendation before receiving the HPV vaccine. After the education the
posttest results improved with the average participant missing less than two questions.
Evaluation of Theoretical Framework
The theoretical framework applied to this project was the Health Belief Model
(HBM). Following this theory, the increase of HPV knowledge will increase HPV
knowledge and vaccination uptake. Education was provided and questions were answered
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about HPV and the possible risk of HPV to the participant. Through education the
participant learned they could avoid possible outcomes of HPV by obtaining the HPV
vaccine. Because of this education there were seven participants that reported they would
obtain the HPV vaccine. This follows the HBM. The education provided to the
participants followed the six concepts. The participants were educated on the research
regarding acquiring HPV and the consequences of HPV. The participants were educated
on the HPV vaccine would protect them from further HPV strains. The participants were
educated on barriers to prevent HPV infections. Evidence based practice research and
guidelines were presented to the participants to assure them the HPV vaccine will protect
them against HPV.
Evaluation of Logic Model
This study measured the participants knowledge of HPV before and after an
educational presentation presented to the fall 2019 health promotion undergraduate
students at Pittsburg State University. The evaluated outcomes measured were knowledge
of HPV and intention of the HPV vaccination after the presentation. There is an
assumption that there will be an increase of HPV and HPV vaccine knowledge in the
students enrolled at Pittsburg State University after this presentation.
Positive outcomes of this study include an increase of HPV and HPV vaccine
knowledge after the presentation as indicated by pretest and posttest scores. Also, several
participants reporting wanting to obtain the HPV vaccine to protect them from HPV. The
project supported the logic model in all outcomes, short and medium. Long term
outcomes were not able to be supported due to time limitations and was not evaluated.
Limitations
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There are several limitations to this study. One limitation is actual vaccination
records were not obtained and self-reported. This could lead to a false number of
vaccinated or unvaccinated participants. There was no follow-up to see if the participants
intending to get the HPV vaccine actually received the HPV vaccine. The pretest and
posttest was also self-reporting and it is assumed the participant answered the questions
honestly and to the best of their knowledge on the surveys. The participant had both the
pretest and posttest, it is assumed that directions were followed, and the pretest was
completed and placed in a yellow envelope and no answers were changed after the
presentation. The majority of the study participants were female, which leaves an unequal
proportion of genders in this study. This study also contains many students involved in
health-related majors which may have contributed to previous knowledge of HPV and the
HPV vaccine. Long term outcomes could not be evaluated due to time constraints.
Implications for Future Projects
Limitations stated above should be addressed for future studies. It would be
appropriate to obtain immunization records of the sample to gain an accurate percentage
of HPV vaccination. The researcher could easily verify if the participant has had the
doses of the HPV vaccine to be fully covered. A follow-up in two months would be
recommended for participants intending to get the HPV vaccine. There could also be
another follow-up in a year to evaluate if they have talked or shared any information of
HPV to anyone since the education was provided to evaluate an increase of HPV in the
general public. Future projects with equal amount of male and female participants would
evaluate if gender specific differences are noted. This project could be repeated in a nonhealth degree seeking college student to evaluate if differences in outcomes occur.
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Implications for Practice/Health Policy/Education
The goal of this project was to increase knowledge of HPV and the HPV vaccine
among college students leading to an increase of HPV vaccination rates. Information of
HPV and the HPV vaccine can be utilized by healthcare providers, future healthcare
providers, and the general public. Results of this project contains important information
to health care providers, policy makers, and the general public. This project reinforced
that the Healthy People 2020 goal of 80% of HPV vaccination uptake is still not being
met.
Conclusion
This project provided participants with evidence-based research regarding HPV
and the HPV vaccine. Studies show there is lack of information that contributes to the
low HPV vaccine uptake. The knowledge gained in this project increased awareness of
HPV and the HPV vaccine. It is possible many of these participants will have careers
healthcare and influence in the uptake of the HPV vaccine. As evidenced by results of
this project more education is needed among college students about HPV and the HPV
vaccine to prevent the spread of HPV and improve the uptake of the HPV vaccine. This
can prevent diseases caused by HPV and even cancer. To stop these outcomes evidencebased research of HPV and the HPV vaccine should be shared, among the community
and healthcare workers.

51

References
AGREE Next Steps Consortium (2013). The AGREE II instrument [Electronic version].
Retrieved from http://www.agreetrust.org.
Britt, R. K., & Britt, B. C. (2016). The need to develop health campaigns for obtaining
the HPV vaccine in rural and medically-underserved college campuses. Education
& Health, 34(3), 74–78. Retrieved from https://search-ebscohostcom.library.pittstate.edu/login.aspx?direct=true&AuthType=ip&db=rzh&AN=11
8948346&site=ehost-live
Centers for Disease Control and Prevention. (2018a). About CDC 24-7. Retrieved from:
https://www.cdc.gov/about/history/index.html
Centers for Disease Control and Prevention. (2018b). HPV coverage data. Retrieved
from: https://www.cdc.gov/hpv/hcp/vacc-coverage/index.html
Centers for Disease Control and Prevention (2018c). HPV vaccines. Retrieved from:
https://www.cdc.gov/hpv/parents/vaccine.html
Centers for Disease Control and Prevention. (2018d). Vaccine safety. Retrieved from:
https://www.cdc.gov/vaccinesafety/vaccines/hpv-vaccine.html
Centers for Disease Control and Prevention. (2018e). Vaccines & immunizations.
Retrieved from: https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm
Centers for Disease Control and Prevention. (2019). Human papillomavirus. Retrieved
from:
https://www.cdc.gov/hpv/hcp/schedulesrecommendations.html?CDC_AA_refVal
=https %3A%2F%2Fwww.cdc.gov%2Fhpv%2Fhcp%2Fclinician-factsheet.html

52

Centers for Disease Control and Prevention. (n.d.). HPV Vaccine information for
clinicians. Retrieved from: https://www.cdc.gov/hpv/hcp/need-to-know.pdf
Erves, J., Mayo-Gamble, T., Hull, P., Duke, L., & Miller, S. (2017). Adolescent
participation in HPV vaccine clinical trials: Are parents willing? Journal of
Community Health, 42(5), 894–901.
https://doiorg.library.pittstate.edu/10.1007/s10900-017-0331-x
Ezeanolue, E., Harriman, K., Hunter, P., Kroger, A., & Pellegrini, C. (2017).
General best practice guidelines for immunizations. Best Practices
Guidance of the Advisory Committee of Immunization Practices (ACIP).
Retrieved from: https://www.cdc.gov/vaccines/hcp/acip-recs/generalrecs/index.html
Forshaw, J., Gerver, S. M., Gill, M., Cooper, E., Manikam, L., & Ward, H. (2017). The
global effect of maternal education on complete childhood vaccination: a
systematic review and meta-analysis. BMC Infectious Diseases, 171-16.
doi:10.1186/s12879-017-2890-y
Franco, M., Mazzucca, S., Padek, M., & Brownson, R. C. (2019). Going beyond the
individual: how state-level characteristics relate to HPV vaccine rates in the
United States. BMC Public Health, 19(1), N.PAG. https://doiorg.library.pittstate.edu/10.1186/s12889-019-6566-y
Gillespie, K. (2018). Adolescent vaccination coverage in Kansas, an analysis of BRFSS
surveys. Kansas Department of Health and Environment.

53

Healthy People 2020. (2014). HPV vaccine, adolescents, 2008-2012. Retrieved from:
https://www.healthypeople.gov/2020/topics-objectives/national-snapshot/hpvvaccine-adolescents-2008%E2%80%932012
Kasymova, S. Harrison, S. E., & Pascal, C. (2019) Knowledge and awareness of human
papillomavirus among college students in South Carolina. Infectious Diseases:
Research & Treatment, 12, N.PAG.
https://doiorg.library.pittstate.edu/10.1177..1178633718825077
Kornides, M. L., Calo, W. A., Heisler-MacKinnon, J. A., & Gilkey, M. B. (2018). U.S.
Primary care clinics’ experiences during introduction of the 9-Valent HPV
vaccine. Journal of Community Health, 43(2), 291–296. https://doiorg.library.pittstate.edu/10.1007/s10900-017-0420-x
Lai, D., Bodson, J., Davis, F., Lee, D., Tavake-Pasi, F., Napia, E., & Kepka, D. (2017).
Diverse families’ experiences with HPV vaccine information sources: A
community-based participatory approach. Journal of Community Health, 42(2),
400–412. https://doi-org.library.pittstate.edu/10.1007/s10900-016-0269-4
Lexico. (2019). Vaccination. Retrieved from:
https://www.lexico.com/en/definition/vaccination
MacArthur, K. R. (2017). Beyond health beliefs: The role of trust in the HPV vaccine
decision-making process among American college students. Health Sociology
Review, 26(3), 321–338. https://doiorg.library.pittstate.edu/10.1080/14461242.2017.1381035

54

McLedo, Saul. (2019). What’s the difference between qualitative and quantitative
research? Retrieved from: https://www.simplypsychology.org/qualitativequantitative.html
National Cancer Institute. (n.d.). NCI dictionary of cancer terms. Retrieved from:
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/humanpapillomavirus
Ogunbajo, A., Hansen, C. E., North, A. L., Okoloko, E., & Niccolai, L. M. (2016). “I
think they’re all basically the same”: Parents’ perceptions of human papilloma
virus (HPV) vaccine compared with other adolescent vaccines. Child: Care,
Health & Development, 42(4), 582–587. https://doiorg.library.pittstate.edu/10.1111/cch.12331
Roncancio, A., Ward, K., Carmack, C., Muñoz, B., Cano, M., & Cribbs, F. (2017). Using
social marketing theory as a framework for understanding and increasing HPV
vaccine series completion among hispanic adolescents: A qualitative study.
Journal of Community Health, 42(1), 169–178. https://doiorg.library.pittstate.edu/10.1007/s10900-016-0244-0
Rosen, B. L., DiClemente, R., Shepard, A. L., Wilson, K. L., & Fehr, S. K. (2017).
Factors associated with school nurses’ HPV vaccine attitudes for school-aged
youth. Psychology, Health & Medicine, 22(5), 535–545. https://doiorg.library.pittstate.edu/10.1080/13548506.2016.1173710
Satterwhite, C.L., Torrone, E., Meites, E., Dunne, E.F., Mahjan, R., Ocfemia, M.C., &
Weinstock, H. (2013). Sexually transmitted infections among US women and
men. Sexually Transmitted Diseases, 40, 187-193.

55

Steinau, M., Unger, E.R., Hernandez, B.Y., Goodman, M.T., Copeland, G., Hopenhayn,
C., Cozen, W., Saber, M.S., Huang, Y., Peters, E.S., Lynch, C.F., Wilkinson, E.
J., Rajeevan, M.S., Lyu, C. & Saraiya, M. (2013). Human papillomavirus
prevalence in invasive anal cancers in the United States before vaccine
introduction. Journal of Lower Genital Tract Disease, 17, 397-403.
University of Twente. (2017). Health belief model. Retrieved from:
https://www.utwente.nl/en/bms/communication-theories/sortedbycluster/Health%20 Communication /Health_Belief_Model/
Ventola, C. L. (2016). Immunization in the United States: Recommendations, barriers,
and measures to improve compliance: Part 1: Childhood vaccinations. Pharmacy
and Therapeutics, 41(7), 426–436.
Wilson, A. R., Hashibe, M., Bodson, J., Gren, L. H., Taylor, B. A., Greenwood, J., &
Kepka, D. (2016). Factors related to HPV vaccine uptake and 3-dose completion
among women in a low vaccination region of the USA: an observational study.
BMC Women’s Health, 16, 1–9. https://doiorg.library.pittstate.edu/10.1186/s12905-016-0323-5
YourDictionary. (2019). College-aged. Retrieved from:
https://www.yourdictionary.com/college-aged

56

APPENDIX

Appendix A:
Pretest –
First initial of mother’s first name:
First initial of mother’s maiden name:
First initial of your middle name (If none, use X):
First initial of place of birth:

Increasing Knowledge About HPV and the HPV Vaccine Amongst College Students
Demographics:
Gender:
Male
Female
Ever heard of HPV?
Yes
No/Do not know
Ever heard of the HPV vaccine?
Yes
No/Do not know
Has a healthcare provider recommended the HPV vaccine to you?
Yes
No/Do not know
Have you received at least once dose of the HPV vaccine?
Yes
No/Do not know
Human Papillomavirus Knowledge Questionnaire (HPV-KQ)
For each statement, please circle “True” (T), “False” (F), or “I don’t know” (DK).
If you do not know, please do not guess, please circle “DK.”
True
1. HPV is a sexually transmitted infection.

T

F

I don’t
know
DK

2. There is a cure for HPV.

T

F

DK

3. Having one type of HPV means that you cannot acquire new
types.
4. There is a screening that is commonly used to test males for
HPV.

T

F

T

F
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False

DK
DK

5. An abnormal Pap smear may indicate that a woman has HPV.

T

F

6. Most genital HPV infections do not clear up on their own.

T

F

DK
DK

7. A person usually has symptoms when infected with HPV.

T

F

DK

8. HPV is not a very common virus.

T

F

DK

9. HPV infection can cause genital warts.

T

F

DK

10. HPV infection can cause genital herpes.

T

F

DK

11. Certain types of HPV can lead to cervical cancer in women.

T

F

DK

12. HPV can lay dormant in the body for years without
symptoms.
13. A person’s chances of getting HPV increase with the number
of sexual partners they have.

T

F

DK

T

F

DK

14. Most people with HPV have visible signs or symptoms of the
infection.

T

F

DK

15. Genital warts can cause cervical cancer.

T

F

DK

16. Condoms are not effective in preventing HPV.

T

F

DK

17. HPV can cause penile cancer.

T

F

DK

18. Nearly all sexually active men and women will contract HPV
at some point.

T

F

DK
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Appendix B:
Posttest–
First initial of mother’s first name:
First initial of mother’s maiden name:
First initial of your middle name (If none, use X):
First initial of place of birth:
If you have not received one does of the HPV vaccine, do you intend to after the
education?
I have already received at least one dose
Yes
No/Do not know
Human Papillomavirus Knowledge Questionnaire (HPV-KQ)
For each statement, please circle “True” (T), “False” (F), or “I don’t know” (DK).
If you do not know, please do not guess, please circle “DK.”
True

False

1. HPV is a sexually transmitted infection.

T

F

2. There is a cure for HPV.

T

F

DK

3. Having one type of HPV means that you cannot acquire new
types.
4. There is a screening that is commonly used to test males for
HPV.
5. An abnormal Pap smear may indicate that a woman has HPV.

T

F

DK

T

F

DK

T

F

DK

6. Most genital HPV infections do not clear up on their own.

T

F

DK

7. A person usually has symptoms when infected with HPV.

T

F

DK

8. HPV is not a very common virus.

T

F

DK

9. HPV infection can cause genital warts.

T

F

DK

10. HPV infection can cause genital herpes.

T

F

DK

11. Certain types of HPV can lead to cervical cancer in women.

T

F

DK
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I don’t
know
DK

12. HPV can lay dormant in the body for years without symptoms.

T

F

DK

13. A person’s chances of getting HPV increase with the number
of sexual partners they have.

T

F

DK

14. Most people with HPV have visible signs or symptoms of the
infection.

T

F

DK

15. Genital warts can cause cervical cancer.

T

F

DK

16. Condoms are not effective in preventing HPV.

T

F

DK

17. HPV can cause penile cancer.

T

F

DK

18. Nearly all sexually active men and women will contract HPV
at some point.

T

F

DK
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Appendix D:
Educational PowerPoint

IN CREASIN G KN OW LEDGE ABOUT
HPV AN D THE HPV VACCIN E AMON GST
COLLEGE STUDEN TS
Morgan Baxter, BSN, RN
BSN to DNP
Pittsburg State University

W HAT IS HPV?

• Virus that infects epithelial tissues of males and females.
• Can cause warts and several different cancers.
• Can be asymptomatic.
• 80 million people have HPV in the United States.
• Every year 14 million contract the virus
• 4,000 women die every year from preventable cervical cancer.
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W HAT IS THE
HPV VACCIN E?
• Three different vaccines to date.
• Current vaccine is the Gardasil 9, approved in
2014 and only one used today
• Protects against HPV types 6, 11, 16, 18, 31,
33, 45, 52, and 58.
• Recommended for people between the ages
of 9 to 26.
• 2 or 3 doses of vaccine to be fully protected
depending on age of initial vaccination
• Healthy People 2020 goal is 80% HPV
vaccination

HPV KN OW LEDGE

• Is HPV a sexually transmitted infection?
• Is there a cure for HPV?
• If you have one type of HPV can you acquire a different type?
• Can males be screened for HPV?
• Can an abnormal pap smear indicate a woman has HPV?
• Do most HPV infections clear up on their own?
• Does a person have symptoms when infected with HPV?
• Is HPV a common virus?
• Can HPV cause genital warts?
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HPV KN OW LEDGE

• Can HPV cause genital herpes?
• Can certain types of HPV lead to cervical cancer in women?
• Can HPV lay dormant in the body for years without symptoms?
• Does the chances of contracting HPV increase with the number of sexual
partners they have?
• Do most people have visible signs or symptoms of the infection?
• Can genital warts cause cervical cancer?
• Can condoms prevent HPV?
• Can HPV cause penile cancer?
• Is it true nearly all sexually active men and women will contract HPV at
some point?

SUMMARY

• HPV IS PREVENTABLE
• Vaccine available, most
insurances covered.

65

